| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Blackstone Inc. (NYSE:BX) is reportedly considering selling the Japanese consumer healthcare firm Alinamin Pharmaceutical Co., previously owned by Takeda Pharmaceutical Company Limited (NYSE:TAK).
Blackstone is collaborating with financial advisers on a potential sale of Tokyo-based Alinamin, which could be valued at approximately ¥300 billion ($1.9 billion), reported Bloomberg, citing sources.
According to the report, Alinamin is also attracting interest from CVC Capital Partners, EQT AB (OTC:EQBBF), and MBK Partners.
Other potential possibilities include an initial public offering of the business. Blackstone may decide not to pursue a deal, the report added.
The report mentioned that Alinamin, which traces its roots back to 1950, launched Japan’s first multivitamin, Panvitan, to combat postwar malnutrition. Its products now include over-the-counter drugs, tonic drinks, pain relievers, smoking cessation aids, laxatives, and medicated bath salts.
Also Read: Blackstone Set To Acquire Japanese E-Comics Giant Infocom For $1.7B: Report.
Blackstone acquired Alinamin from Takeda for ¥242 billion in 2021 as part of Takeda’s asset disposal strategy following its $62 billion purchase of Shire Plc two years prior.
Price Action: BX shares are trading lower by 1.67% at $118.49 at the last check Monday.
Photo via Shutterstock
